Longboard Pharmaceuticals Inc (LBPH) Fundamental Analysis & Valuation

NASDAQ:LBPH • US54300N1037

Current stock price

59.98 USD
+0.02 (+0.03%)
At close:
60.01 USD
+0.03 (+0.05%)
After Hours:

This LBPH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. LBPH Profitability Analysis

1.1 Basic Checks

  • In the past year LBPH has reported negative net income.
  • In the past year LBPH has reported a negative cash flow from operations.
LBPH Yearly Net Income VS EBIT VS OCF VS FCFLBPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -10M -20M -30M -40M -50M

1.2 Ratios

  • LBPH has a Return On Assets (-25.70%) which is comparable to the rest of the industry.
  • LBPH's Return On Equity of -27.74% is fine compared to the rest of the industry. LBPH outperforms 67.71% of its industry peers.
Industry RankSector Rank
ROA -25.7%
ROE -27.74%
ROIC N/A
ROA(3y)-65.03%
ROA(5y)N/A
ROE(3y)-77.12%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LBPH Yearly ROA, ROE, ROICLBPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for LBPH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LBPH Yearly Profit, Operating, Gross MarginsLBPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. LBPH Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, LBPH has more shares outstanding
  • LBPH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
LBPH Yearly Shares OutstandingLBPH Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 5M 10M 15M 20M
LBPH Yearly Total Debt VS Total AssetsLBPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

  • An Altman-Z score of 63.60 indicates that LBPH is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 63.60, LBPH belongs to the best of the industry, outperforming 96.88% of the companies in the same industry.
  • LBPH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 63.6
ROIC/WACCN/A
WACCN/A
LBPH Yearly LT Debt VS Equity VS FCFLBPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

  • LBPH has a Current Ratio of 15.97. This indicates that LBPH is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of LBPH (15.97) is better than 88.54% of its industry peers.
  • LBPH has a Quick Ratio of 15.97. This indicates that LBPH is financially healthy and has no problem in meeting its short term obligations.
  • LBPH has a better Quick ratio (15.97) than 88.54% of its industry peers.
Industry RankSector Rank
Current Ratio 15.97
Quick Ratio 15.97
LBPH Yearly Current Assets VS Current LiabilitesLBPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. LBPH Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 7.85% over the past year.
EPS 1Y (TTM)7.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.55%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, LBPH will show a small growth in Earnings Per Share. The EPS will grow by 2.83% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y4.61%
EPS Next 2Y-10.02%
EPS Next 3Y-10.5%
EPS Next 5Y2.83%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LBPH Yearly Revenue VS EstimatesLBPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M 1B
LBPH Yearly EPS VS EstimatesLBPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4 6 8

More info and screens

Find the best growth stocksShow best growing peers

0

4. LBPH Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for LBPH. In the last year negative earnings were reported.
  • Also next year LBPH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LBPH Price Earnings VS Forward Price EarningsLBPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LBPH Per share dataLBPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

  • A cheap valuation may be justified as LBPH's earnings are expected to decrease with -10.50% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.02%
EPS Next 3Y-10.5%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. LBPH Dividend Analysis

5.1 Amount

  • LBPH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

LBPH Fundamentals: All Metrics, Ratios and Statistics

Longboard Pharmaceuticals Inc

NASDAQ:LBPH (11/29/2024, 7:46:54 PM)

After market: 60.01 +0.03 (+0.05%)

59.98

+0.02 (+0.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-07
Earnings (Next)N/A
Inst Owners101.95%
Inst Owner Change0%
Ins Owners0.04%
Ins Owner Change0%
Market Cap2.34B
Revenue(TTM)N/A
Net Income(TTM)-76.34M
Analysts75.38
Price Target65.96 (9.97%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-15.68%
Min EPS beat(2)-24.62%
Max EPS beat(2)-6.75%
EPS beat(4)1
Avg EPS beat(4)-4.45%
Min EPS beat(4)-24.62%
Max EPS beat(4)15.33%
EPS beat(8)4
Avg EPS beat(8)1.23%
EPS beat(12)5
Avg EPS beat(12)-2.26%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)2.18%
EPS NQ rev (1m)-1.15%
EPS NQ rev (3m)-24.01%
EPS NY rev (1m)-1.17%
EPS NY rev (3m)-7.89%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 8.51
P/tB 8.51
EV/EBITDA N/A
EPS(TTM)-2.23
EYN/A
EPS(NY)-2.88
Fwd EYN/A
FCF(TTM)-1.69
FCFYN/A
OCF(TTM)-1.69
OCFYN/A
SpS0
BVpS7.05
TBVpS7.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -25.7%
ROE -27.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-65.03%
ROA(5y)N/A
ROE(3y)-77.12%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.97
Quick Ratio 15.97
Altman-Z 63.6
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.55%
EPS Next Y4.61%
EPS Next 2Y-10.02%
EPS Next 3Y-10.5%
EPS Next 5Y2.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-65.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-67.64%
EBIT Next 3Y-40.09%
EBIT Next 5Y22.5%
FCF growth 1Y-93.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-93.52%
OCF growth 3YN/A
OCF growth 5YN/A

Longboard Pharmaceuticals Inc / LBPH Fundamental Analysis FAQ

What is the fundamental rating for LBPH stock?

ChartMill assigns a fundamental rating of 3 / 10 to LBPH.


What is the valuation status for LBPH stock?

ChartMill assigns a valuation rating of 0 / 10 to Longboard Pharmaceuticals Inc (LBPH). This can be considered as Overvalued.


How profitable is Longboard Pharmaceuticals Inc (LBPH) stock?

Longboard Pharmaceuticals Inc (LBPH) has a profitability rating of 1 / 10.


How financially healthy is Longboard Pharmaceuticals Inc?

The financial health rating of Longboard Pharmaceuticals Inc (LBPH) is 8 / 10.


Can you provide the expected EPS growth for LBPH stock?

The Earnings per Share (EPS) of Longboard Pharmaceuticals Inc (LBPH) is expected to grow by 4.61% in the next year.